Focused On-demand Library for C-type lectin domain family 4 member D

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8WXI8

UPID:

CLC4D_HUMAN

Alternative names:

C-type lectin superfamily member 8; C-type lectin-like receptor 6; Dendritic cell-associated C-type lectin 3

Alternative UPACC:

Q8WXI8; Q8N5J5

Background:

C-type lectin domain family 4 member D, also known as C-type lectin superfamily member 8, plays a pivotal role in the innate immune system. It acts as a pattern recognition receptor, identifying both damage-associated and pathogen-associated molecular patterns from bacteria and fungi. This protein's interaction with the signaling adapter Fc receptor gamma chain forms a complex that triggers a cascade of immune responses, leading to the maturation of antigen-presenting cells and the priming of T-cells.

Therapeutic significance:

Understanding the role of C-type lectin domain family 4 member D could open doors to potential therapeutic strategies.